

Curriculum Vitae
Jennifer K. Martin, R.D.

Jennifer K Martin RD
5/1/07

Business Address:

National Clinical Research, Inc.
2809 Emerywood Parkway
Suite 140
Richmond, VA 23294
(804) 672-2133 ext. 26

EDUCATION

- 1990 Dietetic Internship
 Medical College of Virginia Hospitals
 Richmond, VA
- 1989 B.S., Dietetics (Graduated Summa Cum Laude)
 Eastern Mennonite College
 Harrisonburg, VA

EXPERIENCE

- 2001 – present Dietitian
 National Clinical Research, Inc.
 Richmond, VA
- 1/1995 – 6/2001 Cancer Center Dietitian
 Rockingham Memorial Hospital Cancer Center
 Harrisonburg, VA
- 6/1993 – 12/1994 Nutrition Support and Oncology Dietitian
 Rockingham Memorial Hospital and Cancer Center
 Harrisonburg, VA
- 1/1991 – 5/1993 Clinical Dietitian
 Medical College of Virginia Hospitals
 Richmond, VA

PROFESSIONAL AFFILIATIONS

- Member of Richmond Dietetic Association
Member of American Dietetic Association

CLINICAL RESEARCH EXPERIENCE

A phase III, 12- month, double blind, randomized, placebo group, placebo controlled, efficacy and safety study of AXOKINE® in overweight and obese subjects with a 12-month open-label extension phase (Protocol AX15-OB-0008), Celeris/Regeneron, Jul01 –

A randomized, double-blind, placebo-controlled, parallel-group, fixed dose, multicenter study of weight-reducing and prevention of weight regain effects and safety of SR141716 in obese patients with or without comorbidities (Protocol EFC4743), ICON/Sanofi~Synthelabo, Sep01 –

A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study of weight-reducing effect and safety of SR141716 in obese patients with type 2 diabetes (Protocol EFC4736), Sanofi~Synthelabo, Oct01 –

A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Short-Term, Efficacy and Safety Study of Two Doses of AXOKINE® in Overweight and Obese Patients with Type 2 Diabetes Mellitus, ICON/Regeneron (Protocol AX15-OB-0201), Aug02.

A Dose Range-Finding, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of L-753721 in Obese Subjects, Merck & Co. (Protocol 006), Sep02.

The Effect of Niacin ER/Lovastatin on Peak Walking Time in Patients with Intermittent Claudication, KOS Pharmaceuticals (Protocol MA-02-010403: ICPOP Study), Dec02 –

The Effects of the Combination of WelChol® and TriCor® Compared to TriCor® Alone in Patients with Mixed Hyperlipidemia, Medpace/Sankyo (Protocol WEL-403), Feb03.

A Double-Blind, Randomized, Active-Controlled MK-0767 and Metformin Comparator Study in Type 2 Diabetic Patients Inadequately Controlled on Diet and Exercise, Merck & Co. (Protocol/Amendment No. 020-01), Mar03.

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate The Safety and Efficacy of MK-0767 added to Sulfonylurea in Patients With Inadequately Controlled Type 2 Diabetes Mellitus, Merck & Co. (Protocol 27), Apr03.

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate The Safety and Efficacy of MK-0767 added to Metformin in Patients With Inadequately Controlled Type 2 Diabetes Mellitus, Merck & Co. (Protocol 28), Apr03.

A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With Hypercholesterolemia, MSP Singapore c/o Merck (Protocol 051), Jun03.

A One-Year, Open, Randomized, Parallel, Three-Arm Study Comparing Exubera® (Insulin Dry Powder Pulmonary Inhaler) vs. Avandia® (rosiglitazone maleate) as Add-On Therapy vs. Exubera® Substitution of Sulfonylurea in Patients with Type 2 Diabetes, Poorly Controlled on Combination Sulfonylurea and Metformin Treatment, Inveresk Research/Pfizer (Protocol 2171017), May03.

A 26-week double blind, randomised, multi-centre, phase IIIb, parallel group study to compare the efficacy and safety of rosuvastatin (40mg) with atorvastatin (80mg) in subjects with hypercholesterolaemia and Coronary Heart Disease or CHD Risk Equivalents, Target Research/Zeneca (Protocol 4522IL/0106), May03.

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK-0767 Added to Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus, Merck & Co. (Protocol 030), May03.

Evaluation of the Efficacy and Safety of Fenofibrate and Ezetimibe Coadministration in Patients with Mixed Hyperlipidemia, MSP Singapore c/o Merck (Protocol 036-01), May03.

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of BMS-298585 as Monotherapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control, Bristol-Myers Squibb (Protocol CV168-018), May03.

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of L-000753721 in Obese Patients, Merck & Co. (Protocol 011), Sep03.

Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Carotid B-Mode Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination Cp-529,414/Atorvastatin, Administered Orally, Once Daily (Qd) For 24 Months, Compared With Atorvastatin Alone, in Subjects with Mixed Hyperlipidemia, Pfizer, Inc. (Protocol A5091004), Sep03.

